BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ooka Y, Chiba T, Ogasawara S, Arai K, Suzuki E, Tawada A, Yamashita T, Kanai F, Kaneko S, Yokosuka O. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. Invest New Drugs 2014;32:723-8. [PMID: 24599799 DOI: 10.1007/s10637-014-0077-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Yue H, Xu S, Wang F, Ma N, Li K, Qiao L, Wang J. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol. 2015;20:952-959. [PMID: 25712158 DOI: 10.1007/s10147-015-0796-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tsai HJ, Shiah HS, Chang JY, Su WC, Chiang NJ, Chen LT. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. Sci Rep 2021;11:4834. [PMID: 33649501 DOI: 10.1038/s41598-021-84279-6] [Reference Citation Analysis]
3 Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol. 2016;777:78-87. [PMID: 26939882 DOI: 10.1016/j.ejphar.2016.02.064] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
4 Azim HA, Omar A, Atef H, Zawahry H, Shaker MK, Abdelmaksoud AK, EzzElarab M, Abdel-Rahman O, Ismail M, Kassem L, Waked I. Sorafenib plus tegafur-uracil (UFT) vs sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). J Hepatocell Carcinoma. 2018;5:109-119. [PMID: 30510922 DOI: 10.2147/jhc.s169285] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
5 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Li JQ, Wu X, Gan L, Yang XL, Miao ZH. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Acta Pharmacol Sin 2017;38:1642-54. [PMID: 28713155 DOI: 10.1038/aps.2017.79] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
7 Fang P, Zhou L, Lim LY, Fu H, Yuan ZX, Lin J. Targeting Strategies for Renal Cancer Stem Cell Therapy. Curr Pharm Des. 2020;26:1964-1978. [PMID: 32188377 DOI: 10.2174/1381612826666200318153106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
9 Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol 2017;15:e2000487. [PMID: 28158308 DOI: 10.1371/journal.pbio.2000487] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
10 El Dika I, Abou-Alfa GK. The role (if any) of chemotherapy in hepatocellular carcinoma. Lancet Gastroenterol Hepatol 2017;2:387-9. [PMID: 28497748 DOI: 10.1016/S2468-1253(17)30104-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]